China Isotope & Radiation Corporation

Equities

1763

CNE1000031F4

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E. Other stock markets 01:40:38 2024-04-26 am EDT			5-day change	1st Jan Change
10.62 ^HKD	+3.31%		+14.81%	-20.51%

Apr. 04	China Isotope & Radiation to Form JV Company	MT
Apr. 03	China Network Group Co., Ltd. Enters into the Investment and Cooperation Agreement with CNNC Hainan Nuclear Power	CI

China Isotope & Radiation Corporation agreed to acquire Ningbo Junan Pharmaceuticals Technology Co., Ltd. from Tibet Juzhi Venture Investment Co., Ltd for CNY 80 million.

January 20, 2019

China Isotope & Radiation Corporation (SEHK:1763) agreed to acquire Ningbo Junan Pharmaceuticals Technology Co., Ltd. from Tibet Juzhi Venture Investment Co., Ltd for CNY 80 million on January 18, 2019. China Isotope & Radiation Corporation will fund the transaction from internal resources. Post completion Ningbo Junan Pharmaceuticals Technology Co., Ltd. will become the wholly owned subsidiary of China Isotope & Radiation Corporation.

Latest news about China Isotope & Radiation Corporation

China Isotope & Radiation to Form JV Company	Apr. 04	MT
China Network Group Co., Ltd. Enters into the Investment and Cooperation Agreement with CNNC Hainan Nuclear Power	Apr. 03	CI
China Isotope & Radiation Corporation Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 06 August 2024	Mar. 27	CI
China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
China Isotope & Radiation Corporation Announces Resignation of Chen Shoulei as Non-Executive Director, Vice Chairman, Members of the Strategy Committee, the Audit and Risk Management Committee and the Legal Affairs Committee of the Board	Mar. 27	CI
China Isotope & Radiation Breath Test Kit Gets a Clinical Approval Nod	Mar. 05	MT
China Isotope & Radiation Corporation Announces Approval by the National Medical Products Administration, Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd	Mar. 04	CI
China Isotope & Radiation Arm Secures Safety License for Production Facility in Xinjiang	Jan. 15	MT
China Isotope & Radiation Subsidiary Secures Compliance Accreditation	Jan. 03	MT
CIRC to Buy Radiation Processing Research and Technology Firm	Dec. 28	MT
China Isotope & Radiation Gets New Direct Controlling Shareholder	Dec. 27	MT
China Isotope & Radiation Corporation Elects Zhang Junqi as an Executive Director	Dec. 22	CI
China Isotope & Radiation Corporation Announces Resignation of Wang Suohui as Director	Dec. 21	CI
China Isotope's Nuclear Energy Project Gets 'Outstanding' Rating	Dec. 07	MT
CIRC Wins ESG Case Award in China	Dec. 07	MT
CIRC Boosts Capital Injection in Financial Company	Nov. 24	MT
China Isotope & Radiation Corporation Announces Executive Changes	Nov. 10	CI
China Isotope & Radiation Corporation Appoints Mr. Fan Guomin Employee Representative Director	Nov. 10	CI
CIRC Renews Multiple Agreements with Controlling Shareholder, Affiliates for Two Years	Nov. 01	MT
China Isotope & Radiation Corporation Enter into the Renewed Supply Agreement with China National Nuclear Corporation	23-10-31	CI
China Isotope & Radiation Corporation Enter into the Renewed Consulting Services FeeFramework Agreement with CNNC Tongxing Nuclear Technology Co., Ltd	23-10-31	CI
China Isotope & Radiation Corporation Enter into the Renewed Carbon-14 Supply Agreement with Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd	23-10-31	CI
China Isotope & Radiation to Sell In Vitro Diagnostic Reagents Firm	23-10-24	MT
CNNC Accuray's Tumor Imaging Device Obtains Registration, Manufacturing License in China	23-09-28	MT
China Isotope & Radiation Reveals Fuzhi Intelligent Nuclear Medicine System at Medical Conference	23-09-26	MT

Chart China Isotope & Radiation Corporation

Duration

Period

Chart China Isotope & Radiation Corporation

More charts

Company Profile

China Isotope & Radiation Corporation is a China-based company mainly engaged in research, development, manufacturing and sales of radiopharmaceuticals and radioactive source products. The Company operates mainly through five segments. The Pharmaceuticals segment is mainly engaged in the manufacture and sales of various radiopharmaceuticals for imaging diagnosis and treatment, urea breath test kits and testers, as well as in vitro diagnostic reagents and kits. The Radioactive Source Product segment is mainly engaged in the production and sales of various radioactive source products, and provides related technical services. The Irradiation segment mainly provides irradiation sterilization services and others. The Radiotherapy Equipment and Related Services segment is mainly engaged in the research and development of radiotherapy equipment. The Independent Medical Laboratory Services and Other Business segment mainly provides independent medical laboratory services.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
CHINA ISOTOPE & RADIATION CORPORATION	-20.51%	420M
BIOMÉRIEUX	-1.09%	12.59B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.53%	7.42B
DIASORIN S.P.A.	+0.45%	5.35B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.37%	4.51B
LANTHEUS HOLDINGS, INC.	+5.16%	4.47B
10X GENOMICS, INC.	-51.93%	3.21B
ANDON HEALTH CO., LTD.	+11.34%	2.71B
VITROLIFE AB	-19.05%	1.96B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.07%	1.73B

Diagnostic & Testing Substances